scholarly journals Real-World Treatment Patterns and Outcomes among Elderly Acute Myeloid Leukemia Patients in the United States

10.5772/63758 ◽  
2016 ◽  
Author(s):  
Sacha Satram-Hoang ◽  
Carolina Reyes ◽  
Deborah Hurst ◽  
Khang Q. Hoang ◽  
Bruno C. Medeiros
Keyword(s):  
United States ◽  
Acute Myeloid Leukemia ◽  
Real World ◽  
Myeloid Leukemia ◽  
The United States ◽  
Treatment Patterns ◽  
Acute Myeloid

scholarly journals Treatment patterns in patients with acute myeloid leukemia in the United States: a cross-sectional, real-world survey

2019 ◽  
Vol 35 (5) ◽  
pp. 927-935 ◽  
Author(s):  
Bruno C. Medeiros ◽  
Bhavik J. Pandya ◽  
Anna Hadfield ◽  
James Pike ◽  
Samuel Wilson ◽  
...  
Keyword(s):  
United States ◽  
Acute Myeloid Leukemia ◽  
Real World ◽  
Myeloid Leukemia ◽  
The United States ◽  
Treatment Patterns ◽  
Cross Sectional ◽  
World Survey ◽  
Acute Myeloid

scholarly journals Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States

2015 ◽  
Vol 94 (7) ◽  
pp. 1127-1138 ◽  
Author(s):  
Bruno C. Medeiros ◽  
Sacha Satram-Hoang ◽  
Deborah Hurst ◽  
Khang Q. Hoang ◽  
Faiyaz Momin ◽  
...  
Keyword(s):  
United States ◽  
Acute Myeloid Leukemia ◽  
Big Data ◽  
Data Analysis ◽  
Myeloid Leukemia ◽  
The United States ◽  
Big Data Analysis ◽  
Treatment Patterns ◽  
Acute Myeloid

Real-world prescribing patterns in acute myeloid leukemia in the United States.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e18524-e18524 ◽  
Author(s):  
Bruno C. Medeiros ◽  
Bhavik J. Pandya ◽  
Anna Hadfield ◽  
Samuel Wilson ◽  
Cynthia Mueller ◽  
...  
Keyword(s):  
United States ◽  
Acute Myeloid Leukemia ◽  
Real World ◽  
High Intensity ◽  
Myeloid Leukemia ◽  
Patient Characteristics ◽  
The United States ◽  
First Line ◽  
Low Intensity ◽  
Acute Myeloid

e18524 Background: The effective treatment of patients with acute myeloid leukemia (AML) remains a challenge in clinical practice. This analysis describes the patient characteristics and real-world use of AML treatments in the United States for patients on high- and low-intensity treatment. Methods: Data from the Adelphi AML Disease-Specific Programme, a real-world, cross-sectional survey conducted between February–May 2015, were analysed. A total of 61 hematologist/hem-oncologists, across academic, non-academic and office-based practice locations, provided data on 457 AML patients. Patient characteristics were derived from physician-completed patient record forms where each physician was asked to provide treatment details, including the treatment intensity, for each line of therapy. Results: A total of 91% (n = 415) of patients included in this analysis were previously untreated for AML. Patients had a mean age of 60 years and been diagnosed with AML for a median of 5.0 months. At first-line induction therapy, over half (53%; n = 241) of the patients were initiated on a high-intensity treatment, the most common regimen being cytarabine plus anthracycline (61%; n = 147). The remaining 47% (n = 216) of patients received a low-intensity induction therapy such as low dose cytarabine monotherapy (28%, n = 61), azacitidine monotherapy (25%, n = 54), or decitabine monotherapy (21%, n = 45). Over half (55%, n = 62) of patients suited to high intensity treatment went on to receive cytarabine monotherapy during the consolidation phase of their first-line treatment. Conclusions: According to treating physicians, the large majority of patients receive traditional, well-established therapies at first-line induction for AML. Whilst cytarabine combinations dominate the high-intensity treatment setting, the hypomethylating agents, azacitidine and decitabine, are frequently used for those more suited to low-intensity treatment.

scholarly journals Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States

2018 ◽  
Vol 71 ◽  
pp. 27-33 ◽  
Author(s):  
Jill A. Bell ◽  
Aaron Galaznik ◽  
Eileen Farrelly ◽  
Marlo Blazer ◽  
Sharanya Murty ◽  
...  
Keyword(s):  
United States ◽  
Acute Myeloid Leukemia ◽  
Elderly Patients ◽  
Economic Burden ◽  
Myeloid Leukemia ◽  
Clinical Care ◽  
The United States ◽  
Routine Clinical Care ◽  
Acute Myeloid

scholarly journals Utilization of initial chemotherapy for newly diagnosed acute myeloid leukemia in the United States

2018 ◽  
Vol 2 (11) ◽  
pp. 1277-1282 ◽  
Author(s):  
Vijaya Raj Bhatt ◽  
Valerie Shostrom ◽  
Krishna Gundabolu ◽  
James O. Armitage
Keyword(s):  
United States ◽  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
The United States ◽  
Insurance Status ◽  
Newly Diagnosed ◽  
Key Points ◽  
Facility Type ◽  
Acute Myeloid

Key Points An analysis of 61 775 adults with AML diagnosed between 2003 and 2011 demonstrated that 25% did not receive any chemotherapy. Factors such as facility type, patients’ race, income, and insurance status were associated with the rates of use of chemotherapy.

Sign in / Sign up

Export Citation Format

Share Document